Case Conversation: Safety and Efficacy of Classical Complement Pathway Inhibition with Sutimlimab in Chronic Immune Thrombocytopenia
This is a recorded version of the webinar on Case Conversation: Safety and Efficacy of Classical Complement Pathway Inhibition with Sutimlimab in Chronic Immune Thrombocytopenia that was presented live on November 9, 2022. The production, accreditation and archiving of this program were made possible through a sponsorship from Sobi. Please scroll all the way down this page to view the archived webinar.
Webinar Date: 11/9/2022
Estimated Time to complete: 1 hour
Format: Archived Webinar
Target Audience: Ob/Gyn providers, pediatric/adolescent gynecologists, hematologists, nurse practitioners, and other healthcare professionals
Chronic/refractory immune thrombocytopenia (ITP) is a rare and pathophysiologically heterogenous disorder with variable responsiveness to available treatments. Sutimlimab, a first-in-class humanized monoclonal anti-C1s IgG4 antibody, selectively inhibits the classical pathway. This Phase 1 study (NCT03275454) assessed safety, efficacy, pharmacokinetics, and pharmacodynamics of biweekly sutimlimab in patients with chronic/refractory ITP with inadequate response to ≥2 therapies (platelet count ≤30×109/L). Twelve patients (median age 42 years) received sutimlimab for a median 20.5 weeks followed by a median 2-week washout period (Part A).
This webinar will further discuss the results, which demonstrate that in some ITP patients’ autoantibodies activate the classical complement pathway, accelerating platelet destruction or impairing platelet production, contributing to treatment failure. C1s inhibition may be a safe and beneficial therapeutic approach for patients with chronic/refractory ITP.
After completing this educational activity, participants should be able to:
- Discuss the data regarding the role complement may play in ITP
- Discuss the data regarding classical pathway inhibition in ITP
- Examine the role of complement-based therapy in future directions for the treatment of ITP
James Bussel, MD
Professor Emeritus, Weill Cornell Medicine
Departments of Pediatrics, Medicine and OB-GYN
Catherine M. Broome, BS, MD
Medical Director Cellular Apheresis, Medstar Georgetown University
Associate Professor of Medicine, Georgetown University